A mid-sized biopharma reformulating an oncology drug needed independent validation of indication prioritization. IQVIA applied a rigorous framework combining commercial data, efficacy benchmarks, cost factors, and expert insights. Workshops ensured alignment and customized guidance. In six weeks—just 12% of the time the sponsor had spent on prior efforts—Iqvia confirmed internal rankings and revealed overlooked considerations. The validation secured executive approval for resource allocation and accelerated trial initiation. This evidence-based approach ensured confidence in development strategy under competitive, resource-limited conditions.

Join for free to read